The lab in Wiesbaden, Germany, will help the pharmaceutical and biopharmaceutical sectors meet regulatory requirements
Analytical and bioanalytical services provider SGS has opened a facility in Wiesbaden, Germany, exclusively for extractables and leachables testing for pharmaceutical and related industries.
SGS previously offered these services from its Taunusstein, Germany laboratory, approximately 20km from the new site, but customer demand has seen the need for a dedicated facility and increased investment in this business.
The 500m2 facility accommodates an increased number of scientists. Equipment and instruments that have been both transferred from Taunusstein, and newly acquired, have been qualified and validated in the new laboratory.
Ongoing projects being undertaken for clients have been successfully transferred to Wiesbaden, and the space vacated at Taunusstein creates an opportunity for SGS to expand its quality control release testing capabilities at that facility.
'This investment, in both a new facility and advanced analytical technologies is in response to increased awareness of regulatory requirements globally and growing customer demand,' said Dr Sheida Hoenlinger, Director, Life Sciences Germany.
'SGS has a very strong reputation within the industry for extractables and leachables testing, and this step, to build a dedicated facility, allows us to offer our clients greater opportunities to identify the unknowns through more sensitive and accurate impurity profiling techniques.'
The new facility in Wiesbaden will be SGS’s global Center of Excellence for Extractable Studies and Impurities Profiling, as a hub across the global network of laboratories.
The company runs 21 laboratories offering contract analytical and bioanalytical services for a range of industries throughout North America, Europe, and Asia.